Coadministration with Delstrigo has not been studied. Coadministration of doravirine with ritonavir increased doravirine AUC by 3.5 fold and Cmin by 2.9 fold. No dose adjustment of doravirine is required as phase I trials showed a good tolerability of doravirine with up to a 3-4 fold increase in exposure. Coadministration of lamivudine (in combination with abacavir) and ombitasvir and paritaprevir/r had no effect on the pharmacokinetic parameters of lamivudine, ombitasvir, and paritaprevir/r. Tenofovir-DF can be administered with ombitasvir/paritaprevir/ritonavir and no dose alteration is required. No significant interactions were seen in clinical studies. Coadministration of ombitasvir/paritaprevir/ritonavir with emtricitabine/tenofovir-DF (200/300 mg once daily) decreased tenofovir Cmax by 20% and increased AUC and Cmin by 1% and 13%. Paritaprevir Cmax, AUC and Cmin increased by 2%, 4% and 9%. Similarly, coadministration of lamivudine (in combination with abacavir) and ombitasvir and paritaprevir/r had no effect on the pharmacokinetic parameters of lamivudine, ombitasvir, and paritaprevir/r.